[go: up one dir, main page]

HUP9800744A2 - Fas-antigén elleni antitestek - Google Patents

Fas-antigén elleni antitestek

Info

Publication number
HUP9800744A2
HUP9800744A2 HU9800744A HUP9800744A HUP9800744A2 HU P9800744 A2 HUP9800744 A2 HU P9800744A2 HU 9800744 A HU9800744 A HU 9800744A HU P9800744 A HUP9800744 A HU P9800744A HU P9800744 A2 HUP9800744 A2 HU P9800744A2
Authority
HU
Hungary
Prior art keywords
fas
antibodies
subject
humanized antibodies
prevention
Prior art date
Application number
HU9800744A
Other languages
English (en)
Inventor
Hideyuki Haruyama
Kimihisa Ichikawa
Jun Ohsumi
Masahiko Ohtsuki
Nobufusa Serizawa
Akio Shiraishi
Tohru Takahashi
Shin Yonehara
Hiroko Yoshida
Original Assignee
Sankyo Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company Limited filed Critical Sankyo Company Limited
Publication of HU9800744D0 publication Critical patent/HU9800744D0/hu
Publication of HUP9800744A2 publication Critical patent/HUP9800744A2/hu
Publication of HUP9800744A3 publication Critical patent/HUP9800744A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgyát Fas-antigént felismerő antitestek (elsősőrbanhűmanizált antitestek) és azők fragmensei képezik, tővábbá az ilyenantitestek egészét vagy részét kódőló DNS-ek, a DNS-eket tartalmazórekőmbináns DNS-vektőrők, valamint az ilyen rekőmbináns vektőrőkkaltranszfőrmált gazdasejtek. A találmány tárgyát képezik tővábbá a találmány szerinti antitestekettartalmazó hatóanyagők, amlyek a Fas/Fas-ligandűm rendszerrendellenességeiből adódó betegségek megelőzésére és/vagy kezelésérealkalmazhatók. Szintén a találmány tárgyát képezik a találmányszerinti antitestek előállítási eljárásai. A találmány tárgya, Fas-antigén elleni hűmanizált antitestekalkalmasak a Fas/Fas-ligandűm rendszer rendellenességei őkőztabetegségek kezelésére és/vagy megelőzésére. A találmány szerintihűmanizált antitestek alkalmazása a HAMA-reakció indűkálódásánakminimális kőckázatával jár. ŕ
HU9800744A 1997-04-01 1998-04-01 Antibodies against fas-antigene HUP9800744A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8295397 1997-04-01
JP16908897 1997-06-25
JP27606497 1997-10-08

Publications (3)

Publication Number Publication Date
HU9800744D0 HU9800744D0 (en) 1998-05-28
HUP9800744A2 true HUP9800744A2 (hu) 1999-02-01
HUP9800744A3 HUP9800744A3 (en) 2001-04-28

Family

ID=27304060

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9800744A HUP9800744A3 (en) 1997-04-01 1998-04-01 Antibodies against fas-antigene

Country Status (17)

Country Link
EP (1) EP0909816A1 (hu)
KR (1) KR19980080993A (hu)
CN (1) CN1207395A (hu)
AR (1) AR010139A1 (hu)
AU (1) AU734758B2 (hu)
BR (1) BR9803296A (hu)
CA (1) CA2233783A1 (hu)
CZ (1) CZ294340B6 (hu)
HU (1) HUP9800744A3 (hu)
ID (1) ID20117A (hu)
IL (1) IL123888A0 (hu)
NO (1) NO981454L (hu)
NZ (1) NZ330095A (hu)
PL (1) PL325667A1 (hu)
RU (1) RU2212412C2 (hu)
TR (1) TR199800604A3 (hu)
TW (1) TW526205B (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
PT1049717E (pt) * 1998-01-23 2007-05-31 Hoffmann La Roche Anticorpos contra a il-12 humana.
ES2306515T3 (es) * 1998-06-18 2008-11-01 Imed Ab Peptidos fas y anticuerpos para la modulacion de la apoptosis.
AU757961B2 (en) * 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
BR0010909A (pt) 1999-05-24 2002-02-19 Sankyo Co Composição farmacêutica, agente que tem atividade indutora de apoptose, e, uso de um anticorpo fas anti-humano
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US20070129291A1 (en) * 2001-08-01 2007-06-07 Genset S.A. Genobix agonists and antagonists for use in the treatment of metabolic disorders
EP2383290B1 (en) 2001-08-23 2019-05-08 Rsr Limited Epitope regions of a thyrotropin (tsh) receptor, uses thereof and antibodies thereto
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
WO2005068503A2 (en) 2004-01-07 2005-07-28 Chiron Corporation M-csf-specific monoclonal antibody and uses thereof
CA2732715C (en) * 2008-08-01 2015-04-07 Kusuki Nishioka Treatment agent or preventative agent for osteoarthritis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU705114B2 (en) * 1993-10-14 1999-05-13 Immunex Corporation Fas antagonists and uses thereof
ATE387458T1 (de) * 1994-01-07 2008-03-15 Mochida Pharm Co Ltd Fas-antigenbindender ligand
AU6091496A (en) * 1995-06-07 1996-12-30 Chiron Corporation Antibodies to fas antigen capable of inhibiting apoptosis
GB9523469D0 (en) * 1995-11-16 1996-01-17 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
PL325667A1 (en) 1998-10-12
CZ294340B6 (cs) 2004-12-15
TW526205B (en) 2003-04-01
KR19980080993A (ko) 1998-11-25
EP0909816A1 (en) 1999-04-21
TR199800604A2 (xx) 1999-10-21
HUP9800744A3 (en) 2001-04-28
TR199800604A3 (tr) 1999-10-21
CN1207395A (zh) 1999-02-10
ID20117A (id) 1998-10-01
AR010139A1 (es) 2000-05-17
NZ330095A (en) 1998-12-23
AU5970198A (en) 1998-10-08
NO981454L (no) 1998-10-02
NO981454D0 (no) 1998-03-31
BR9803296A (pt) 2000-01-11
CZ98598A3 (cs) 1998-10-14
IL123888A0 (en) 1998-10-30
AU734758B2 (en) 2001-06-21
CA2233783A1 (en) 1998-10-01
RU2212412C2 (ru) 2003-09-20
HU9800744D0 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
WO2000036107A3 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
WO2002006317A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
HUP0103758A2 (hu) Neurotróf faktorok
ATE209680T1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
EP1067182A8 (en) Secretory protein or membrane protein
HUP9800744A2 (hu) Fas-antigén elleni antitestek
GR3034349T3 (en) Neutralizing monoclonal antibodies to respiratory syncytial virus
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
WO2002057453A3 (en) Polypetides and nucleic acids encoding same
DE69840509D1 (de) Apoptose-bezogene verbindungen und deren verwendung
WO2003089575A3 (en) Antibodies that specifically bind to tl5
WO2002078526A3 (en) Cancer-testis antigens
WO2003102136A3 (en) Antibodies that specifically bind to neurokinin b
NZ302821A (en) isolated truncated nucleic acid molecules which code for GAGE tumour rejection antigen precursors
WO2004015060A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
HUP9700676A2 (hu) Rekombináns anti-Fas antitestek és az ezeket kódoló DNS
WO1998011234A3 (en) Human protein kinases
WO2001029217A3 (en) Novel polypeptides and polynucleotides encoding same
WO2003092597A3 (en) Antibodies that specifically bind to chemokine beta-4
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
WO2002079398A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002081625A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
WO2002010216A3 (en) Proteins and nucleic acids encoding same
WO2002099062A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees